NCT03545087 - A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants | Biotech Hunter

Timeline

Start Date

June 30, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

Renal Insufficiency

Interventions

DRUG

Lanabecestat

Administered orally

DRUG

Iohexol

Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.

Trial Locations (3)

Orlando Clinical Research Ctr., Orlando

Clinical Pharmacology of Miami, Miami

Orange County Research Center, Tustin